Eli Lilly & Co. reported that a host of products launched since 2014 made up 35% of its third quarter revenue and drove 14% volume growth in the company’s pharmaceutical business, but the success of Trulicity (dulaglutide) in a cardiovascular outcomes trial (CVOT) overshadowed the company's earnings report on Nov. 6.
Lilly revealed a day earlier that the GLP-1 agonist – now its top-selling drug – demonstrated superiority compared to placebo...








